Table 5

Disease- or treatment related concomitant medication as reported by physicians

Cycle

N

Analgesics n (%)

Antiemetics n (%)

Antidiarrheals n (%)

Dexa or similar steroids n (%)

CSF n (%)

Other medications n (%)

RBC transfusions n (%)

Platelet transfusions n (%)

Overall

521

387 (74.3)

435 (83.5)

66 (12.7)

496 (95.2)

58 (11.1)

292 (56.0)

126 (24.2)

18 ( 3.5)

Baseline

521

270 (51.8)

182 (34.9)

6 ( 1.2)

244 (46.8)

12 ( 2.3)

187 (35.9)

48 ( 9.2)

5 ( 1.0)

Cycle 1

516

265 (51.4)

270 (52.3)

7 ( 1.4)

452 (87.6)

5 ( 1.0)

196 (38.0)

20 ( 3.9)

2 ( 0.4)

Cycle 2

471

242 (51.4)

288 (61.1)

20 ( 4.2)

430 (91.3)

14 ( 3.0)

201 (42.7)

26 ( 5.5)

0 ( 0.0)

Cycle 3

421

226 (53.7)

260 (61.8)

16 ( 3.8)

391 (92.9)

14 ( 3.3)

186 (44.2)

29 ( 6.9)

4 ( 1.0)

Cycle 4

344

178 (51.7)

215 (62.5)

15 ( 4.4)

327 (95.1)

17 ( 4.9)

155 (45.1)

30 ( 8.7)

3 ( 0.9)

Cycle 5

278

142 (51.1)

179 (64.4)

8 ( 2.9)

268 (96.4)

11 ( 4.0)

137 (49.3)

14 ( 5.0)

1 ( 0.4)

Cycle 6

254

129 (50.8)

168 (66.1)

7 ( 2.8)

244 (96.1)

9 ( 3.5)

125 (49.2)

15 ( 5.9)

0 ( 0.0)

Cycle 7

150

93 (62.0)

87 (58.0)

4 ( 2.7)

143 (95.3)

4 ( 2.7)

96 (64.0)

7 ( 4.7)

0 ( 0.0)

Cycle 8

135

88 (65.2)

64 (47.4)

5 ( 3.7)

131 (97.0)

4 ( 3.0)

87 (64.4)

6 ( 4.4)

1 ( 0.7)

Cycle 9

110

75 (68.2)

52 (47.3)

2 ( 1.8)

105 (95.5)

1 ( 0.9)

77 (70.0)

4 ( 3.6)

0 (0.0)

Final

516

289 (56.0)

253 (49.0)

21 ( 4.1)

317 (61.4)

25 ( 4.8)

203 (39.3)

60 (11.6)

8 ( 1.6)

CSF colony stimulating factors, Dexa dexamethasone, N = number of patients per cycle, RBC red blood cells

Schuette et al. BMC Cancer 2012 12:14   doi:10.1186/1471-2407-12-14